AGENDA DAY 2

 

Day Two 11th October, Human

09:00

Chair’s opening remarks

Panel discussion
09:10

Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia

 
  • The role of emerging markets in the global supply and demand for vaccines
  • What vaccine technologies and vaccine candidates are favourable?
  • Does it align with other philanthropy organisations?
  • The role of Public-Public Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs)
  • Priorities for linking new vaccine development with public health in low and middle income countries
Dr Philip Minor
10:10

Where are we in polio eradication? What are the remaining challenges?

  • How we will maintain a polio-free world
  • Are new/different vaccines required in the post eradication era?
10:40

Morning Break

11:40

Interactive Roundtables

Choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 45 minutes so you can join two discussions in the allotted time. The same roundtables will be run twice back to back.

Incorporating “passive immunization” with vaccines – the use of Phage therapies and mABs
Dr Eszter Nagy, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH

The significant role of the microbiome in disease prevention, treatment and therapeutic development
Jeff Riley, CEO, Synthetic Biologics, Inc.

The regulators relationship with Challenge Studies; yesterday, today and tomorrow
Bruno Speder, Head Clinical Regulatory Affairs, SGS Life Sciences
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

 Advanced veterinary therapies: stem cells, monoclonal antibodies and bacterial phages for veterinary use     
Dr Rosario Bullido, Head of Veterinary Inmunological Medicines Assessment Unit, AEMPS

Intradermal delivery of therapeutic vaccines – benefits and challenges
Dr Kirsty V Gapp, Global Business Manager Transdermal and Microneedle Drug Delivery, 3M 

Porcine T lymphocytes – analysis of their response after vaccination
Prof Dr Armin Saalmüller, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

Using an autologous cancer vaccine to enhance immunotherapy outcomes and tackle a re-occurring disease within companion animals
Dr Patrick Frayssinet, R&D Director

Developing vaccines to emerging diseases and effective use of animal models

Professor Miles W Carroll, Head of Research, Deputy Director, National Infections Service, Public Health England

Trends in mammalian cell culture based vaccines
Ron Geven, BD Biosciences
Dr James W. Brooks, R&D Manager, BD Biosciences

Progress on Zika vaccine development
Dr Gregory Poland, Director, Mayo Clinic
 
Sponsor/CRO Partnership Optimization
Marc Hoffman, CMO, Celerion
Bernhard Liegl, VP Global Clinical Development, Celerion
Susanne Eder-Lingelbach, Head of Clinical Operations, Valneva
13:10

Networking Lunch & Poster Session

EMERGING & RE-EMERGING

CLINICAL DEVELOPMENT IN VIRAL VACCINES

EARLY DEVELOPMENT & MANUFACTURING

Emerging & Re-emerging Diseases
14:40

Chair’s opening remarks

BIOPREPAREDNESS AND VACCINE PROGRESSION

CLINICAL OUTCOMES IN VIRAL VACCINES

NEW PLATFORMS AND PROCESS DEVELOPMENT

Emerging & Re-emerging Diseases
14:45

Development of live measles vaccine vector for new emerging pathogens

  • Developing attenuated measles Schwarz vaccine virus into a versatile chimeric or recombinant vector
  • Proof of concept in humans
  • The potential of measles vector as a platform for rapid response to new pathogens
Clinical Development in Viral Vaccines
15:15

The problem with powering…PhII to PhIII, quo vadis?

Identifying contributing factors to late phase failure and to provide some insights into models for future Phase II trials to better evidence efficacy in the field
Early Development & Manufacturing
15:15

How Innovative Process Development Allows for a Novel Cost-effective Rotavirus Vaccine

The development of novel technologies within biotechnology is highly dynamic, but implementation of these innovations into a manufacturing process stays behind. Three novel technologies are linked to create a simple, but robust, automated vaccine manufacturing platform that can deliver high yields at low cost. The technology platform links mammalian cell lines used for vaccine production in a compact, high cell density bioreactor, and affinity purification into a cost effective automated vaccine manufacturing system in a self-contained miniaturized facility. Polio vaccine production will be used to showcase the new miniaturized production system.
 
15:45

Networking Break

Emerging & Re-emerging Diseases
16:15

Developing a universal vaccine  against emerging mosquito-transmitted diseases and influenza

 
  • Clinical update and approach taken
  • Scientific analysis and trial design
  • Feedback on fast track development and regulatory programmes
  • Next steps and applications
Early Development & Manufacturing
16:30

The rise of RNA vaccines: Practical considerations in bioprocessing and production

Emerging & Re-emerging Diseases
16:45

From vaccines research to launch of Dengvaxia and collaborative efforts to create a Zika vaccine

  • The Dengvaxia research to launch journey: Lessons learned
  • Implications for the future of dengue control
  • Flavivirus Epidemics Preparedness : Developing a Zika vaccine – current status
Clinical Development in Viral Vaccines
16:45

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology

- Virospot Assay platform and principles
- Application: RSV Virospot neutralization
- WHO Micro Neutralization and Virospot Micro Neutralization Assay
Emerging & Re-emerging Diseases
17:15

Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development


 
Dr James Cummings, Vice President, Clinical Development and Translational Medicine, Novavax
17:45

Chair’s closing remarks followed by Meet & Greet with key speakers in the Exhibition Hall

last published: 08/Oct/17 16:35 GMT